ClinicalTrials.gg

Program

AJ201

A development code. Also written as “ALZ002 DS”.

Its studies are mostly in Bulbo-Spinal Atrophy, X-Linked, led by AnnJi Pharmaceutical.

Furthest: phase 2, since Aug 23, 20223 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AnnJi Pharmaceutical31 open or runningphase 2since Aug 23, 2022May 10, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2020First study: phase 1 study in HealthyFirst studyNCT04392830 · 72 enrolled · Australia
  2. Aug 23, 2022Phase 2 study in Bulbo-Spinal Atrophy, X-LinkedNCT05517603 · 25 enrolled · United States
  3. Apr 19, 2026Phase 1 study in Healthy Male AdultsNCT07549919 · 26 planned · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07549919Healthy Male Adults · United States1RecruitingApr 22, 202626
NCT05517603Bulbo-Spinal Atrophy, X-Linked · United States2CompletedApr 8, 202425
NCT04392830Healthy · Australia1CompletedApr 28, 202172

How it is read

Names in the registry

  • “AJ201”, 2 entries
  • “ALZ002 DS”, 1 entry

Codes read as this program: AJ201, ALZ002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.